New pill may replace steroids for severe colitis flares

NCT ID NCT07546097

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if upadacitinib, a newer pill, works as well as standard steroid injections for treating sudden, severe flare-ups of ulcerative colitis. About 46 adults with acute severe colitis will receive either upadacitinib or steroids for 3 months, with frequent checkups. The goal is to see if upadacitinib can quickly calm symptoms like diarrhea and bleeding with fewer side effects, though ongoing medication is still needed to manage the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE SEVERE ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 3201 Hospital

    RECRUITING

    Hanzhong, Shaanxi, 710005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ankang Central Hospital

    RECRUITING

    Ankang, Shaanxi, 710005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shaanxi Provincial Nuclear Industry 215 Hospital

    RECRUITING

    Xianyang, Shaanxi, 710005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Xijing Hospital

    RECRUITING

    Xi'an, Shaanxi, 710005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••